Uliledlimab is a humanized monoclonal antibody with potent inhibitory activity against CD73, the ecto-5-nucleotidase enzyme that catalyzes the conversion of extracellular AMP to adenosine. Uliledlimab reduces extracellular adenosine production, thereby modulating immunosuppressive pathways. Uliledlimab holds significant potential for use in immuno-oncology and cancer research.
Reinheit:
95.00%
CAS Nummer:
[2378407-27-1]
Target-Kategorie:
cAMP|||CD73
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten